These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21345300)

  • 21. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
    Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
    Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA; Katsicas MM
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
    Shenoi S; Wallace CA
    Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.
    Katsicas MM; Russo RA
    Clin Rheumatol; 2009 Aug; 28(8):985-8. PubMed ID: 19322622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C; Buonuomo PS; Tozzi AE; Pardeo M; Nicolai R; Campana A; Insalaco A; Cortis E; DE Benedetti F
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
    Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
    Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
    Matsuno H
    Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.
    Giménez-Roca C; Iglesias E; Torrente-Segarra V; Bou R; Sánchez-Manubens J; Calzada-Hernández J; Hernández S; Ricart S; Antón J
    Rheumatol Int; 2015 Feb; 35(2):323-6. PubMed ID: 25086629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis.
    Haapasaari J; Kautiainen H; Hannula S; Pohjankoski H; Hakala M
    Clin Exp Rheumatol; 2002; 20(6):867-70. PubMed ID: 12508784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
    Geikowski T; Becker I; Horneff G;
    Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.